← Chemomab Therapeutics Ltd.
| Annual Trend | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | |||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | |||||||||||
| Net Income From Continuing Operations | ($9.8m) | ($13.3m) | ($27.1m) | ($11.6m) | ($12.5m) | ($27.6m) | ($24.2m) | ($13.9m) | ($9.0m) | ($9.0m) | |
| Net loss for the year | — | — | — | — | ($12.5m) | ($27.6m) | ($24.2m) | ($13.9m) | ($9.0m) | — | |
| Depreciation | — | — | $281k | $80k | $34k | $58k | $67k | $53k | $70k | $70k | |
| Share-based Payment Arrangement, Noncash Expense | — | — | $1.2m | ($20k) | $2.0m | $3.2m | $1.5m | $617k | $623k | $623k | |
| Adjustments For Share-Based Payments | $730k | $1.9m | — | — | — | — | — | — | — | — | |
| Share-based Payment Arrangement, Expense | — | — | $1.2m | ($20k) | $2.0m | $3.2m | $1.5m | $617k | $623k | $623k | |
| Share-based compensation | — | — | — | — | $2.0m | $3.2m | $1.5m | $617k | $623k | $623k | |
| Operating Lease, Impairment Loss | — | — | — | $278k | $345k | $17k | $392k | — | — | — | |
| Nonoperating Income (Expense) | — | — | — | — | — | $353k | $1.2m | $794k | $572k | — | |
| Change In Working Capital | — | — | — | — | — | $4.0m | ($948k) | ($2.1m) | ($2.8m) | ($2.8m) | |
| Change in other receivables and prepaid expenses | — | — | — | — | ($2.1m) | ($64k) | $903k | ($487k) | ($1.1m) | — | |
| Receivables on account of shares issued, net | — | — | — | — | — | — | $0 | $0 | $44k | — | |
| Change In Receivables | — | — | — | — | — | ($64k) | $903k | ($487k) | ($1.1m) | ($1.1m) | |
| Change in Accounts Payable | — | — | — | — | $1.2m | $352k | ($1.2m) | $150k | ($177k) | — | |
| Change In Payables And Accrued Expense | — | — | — | — | — | $3.2m | ($1.1m) | ($1.8m) | ($1.4m) | ($177k) | |
| Change in accrued expenses | — | — | — | — | ($1.3m) | $2.8m | $45k | ($1.9m) | ($1.2m) | ($1.2m) | |
| Net Cash Provided by (Used in) Operating Activities | — | ($14.7m) |
($16.5m)
-11.63%
|
($12.7m)
+22.76%
|
($12.4m)
+2.66%
|
($20.4m)
-64.62%
|
($23.6m)
-15.91%
|
($15.4m)
+34.84%
|
($11.1m)
+27.66%
|
($11.1m)
0.00%
|
|
| Cash flows from investing activities: | |||||||||||
| Gain (Loss) on Disposition of Property Plant Equipment | — | — | — | $36k | — | — | $0 | $0 | — | — | |
| Payments to Acquire Property, Plant, and Equipment | — | — | $95k | $34k | $239k | $68k | $3k | $0 | $3k | ($3k) | |
| Cash, Cash Equivalents, and Short-term Investments | — | — | — | — | — | — | — | $14.3m | $10.4m | — | |
| Net Other Investing Changes | — | — | — | — | — | $19.6m | $15.9m | $2.3m | $5.4m | $5.4m | |
| Net Cash Provided by (Used in) Investing Activities | — | — | ($95k) | $102k | ($45.2m) | $19.5m | $15.9m | $2.3m | $5.4m | $5.4m | |
| Cash flows from financing activities: | |||||||||||
| Proceeds From Borrowings Classified As Financing Activities | — | $4.0m | — | — | — | — | — | — | — | — | |
| Repayments Of Borrowings Classified As Financing Activities | — | $4.0m | — | — | — | — | — | — | — | — | |
| Issuance Of Capital Stock | — | — | — | — | — | $267k | $3.5m | $9.9m | $7.1m | $7.1m | |
| Repurchase Of Capital Stock | — | — | — | — | $0 | ($1.2m) | $0 | $0 | — | $0 | |
| Proceeds from Issuance of Common Stock | — | — | $30.5m | $0 | — | — | — | — | — | $7.1m | |
| Common Stock Issuance | — | — | — | — | — | $267k | $3.5m | $9.9m | $7.1m | $7.1m | |
| Common Stock Payments | — | — | — | — | $0 | ($1.2m) | $0 | $0 | — | $0 | |
| Net Cash Provided by (Used in) Financing Activities | — | — | $26.6m |
$297k
-98.88%
|
$61.1m
+20463.64%
|
($808k)
-101.32%
|
$3.5m
+533.66%
|
$9.9m
+181.62%
|
$7.2m
-27.47%
|
$7.2m
0.00%
|
|
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | — | — | $10.1m | ($12.3m) | $3.5m | ($1.6m) | ($4.2m) | ($3.2m) | $1.4m | $7.6m | |
| Beginning Cash Position | — | — | — | — | — | $15.2m | $13.6m | $9.4m | $6.1m | $6.1m | |
| Cash, cash equivalents and restricted cash at beginning of the year | — | — | — | — | $15.2m | $13.6m | $9.4m | $6.1m | $7.6m | — | |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | — | — | $17.7m | $5.4m | $15.2m | $13.6m | $9.4m | $6.1m | $7.6m | $7.6m | |
| Change in cash, cash equivalents and restricted cash | — | — | — | — | $3.5m | ($1.6m) | ($4.2m) | ($3.2m) | $1.4m | — | |
| Additional Supplementary Disclosures | |||||||||||
| Additional Supplementary Disclosures | |||||||||||
| Adjustments For Income Tax Expense | $323k | $621k | — | — | — | — | — | — | — | — | |
| Income Tax Expense (Benefit) | — | — | — | $0 | — | ($534k) | $0 | $0 | $0 | — | |
| Operating Lease, Expense | — | — | — | $242k | — | — | — | — | — | — | |
| Change in operating leases | — | — | — | — | ($2k) | ($11k) | $13k | $35k | ($35k) | — | |
| Additional Financial Items | |||||||||||
| Proceeds from Stock Options Exercised | — | — | — | — | $10k | $143k | $0 | $0 | $12k | — | |
| Adjustments For Finance Costs | $259k | ($641k) | — | — | — | — | — | — | — | — | |
| Adjustments For Increase Decrease In Trade Account Payable | $44k | $287k | — | — | — | — | — | — | — | — | |
| Foreign Currency Transaction Gain (Loss), before Tax | — | — | ($40k) | — | — | — | — | — | — | — | |
| General and Administrative Expense | $3.2m | $5.5m | $6.2m | $7.2m | $6.0m | $11.6m | $7.1m | $3.4m | $3.7m | — | |
| Interest Received Classified As Operating Activities | $1k | $11k | — | — | — | — | — | — | — | — | |
| Operating Expenses | — | — | $22.9m | $11.7m | $12.4m | $28.5m | $25.5m | $14.7m | $9.6m | — | |
| Proceeds From Issuing Shares | $5.7m | $10.9m | — | — | — | — | — | — | — | — | |
| Capital Loss | — | — | — | — | — | — | $0 | $0 | $7k | — | |
| Change in employees and related expenses | — | — | — | — | $215k | $907k | ($737k) | $51k | ($278k) | — | |
| Decrease in short-term deposits | — | — | — | — | — | — | $15.9m | $2.3m | $5.4m | — | |
| Proceeds from Stock Issuance | — | — | — | — | $10k | $143k | $0 | $0 | $12k | — | |
| Purchase of treasury share | — | — | — | — | $0 | ($1.2m) | $0 | $0 | — | — | |
| Sale of treasury share | — | — | — | — | $0 | $0 | $580k | $0 | $0 | — | |
| Issuance of shares net of issuance costs | — | — | — | — | $58.6m | $267k | $2.9m | $9.9m | $7.1m | — | |
| Income taxes received | — | — | — | — | $0 | $351k | $187k | $0 | $0 | — | |
| Interest received | — | — | — | — | $74k | $972k | $1.5m | $814k | $610k | — | |
| Right-of-use asset recognized with corresponding lease liability | — | — | — | — | $345k | $17k | $392k | $0 | $0 | — | |
| Issuance costs not paid in cash | — | — | — | — | — | — | $0 | $0 | $32k | — | |
| Cash Flow From Continuing Financing Activities | — | — | — | — | — | ($808k) | $3.5m | $9.9m | $7.2m | $7.2m | |
| Cash Flow From Continuing Investing Activities | — | — | — | — | — | $19.5m | $15.9m | $2.3m | $5.4m | $5.4m | |
| Change In Account Payable | — | — | — | — | — | $352k | ($1.2m) | $117k | ($177k) | ($177k) | |
| Change In Other Working Capital | — | — | — | — | — | $896k | ($724k) | $146k | ($313k) | ($313k) | |
| Change In Payable | — | — | — | — | — | $352k | ($1.2m) | $117k | ($177k) | ($177k) | |
| Changes In Cash | — | — | — | — | — | ($1.6m) | ($4.2m) | ($3.2m) | $1.4m | $1.4m | |
| End Cash Position | — | — | — | — | — | $13.6m | $9.4m | $6.1m | $7.6m | $7.6m | |
| Financing Cash Flow | — | — | — | — | — | ($808k) |
$3.5m
+533.66%
|
$9.9m
+181.62%
|
$7.2m
-27.47%
|
$7.2m
0.00%
|
|
| Free Cash Flow | — | — | — | — | — | ($20.4m) | ($23.6m) | ($15.4m) | ($11.1m) | ($11.1m) | |
| Investing Cash Flow | — | — | — | — | — | $19.5m | $15.9m | $2.3m | $5.4m | $5.4m | |
| Net PPE Purchase And Sale | — | — | — | — | — | ($68k) | ($3k) | $0 | ($3k) | ($3k) | |
| Proceeds From Stock Option Exercised | — | — | — | — | — | $143k | $0 | $0 | $12k | $12k | |
| Purchase Of PPE | — | $213k | $95k | $34k | $239k | ($68k) | ($3k) | $0 | ($3k) | ($3k) | |
| Sale Of PPE | — | — | — | — | $4k | $0 | $0 | $0 | — | $0 | |
| Stock Based Compensation | — | — | — | — | — | $3.2m | $1.5m | $617k | $623k | $623k | |
| Net Investment Purchase And Sale | — | — | — | — | ($46.0m) | $19.6m | — | — | — | — | |
| Supplemental disclosure of cash flow information: | |||||||||||
| Change In Cash Supplemental As Reported | — | — | — | — | — | ($1.6m) | ($4.2m) | ($3.2m) | $1.4m | — | |
| Interest Paid Classified As Operating Activities | — | $22k | — | — | — | — | — | — | — | — | |
| Income Taxes Paid, Net | $362k | $244k | $161k | $84k | $0 | $5k | — | — | — | — |